Skip to main content

AVB500-OC-004 A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)

NCT04729608

A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)

Principal Investigator

Robert Holloway

Sponsor

Aravive AVB500-OC-004

The purpose of this research study is to evaluate the safety and efficacy of an investigational drug called AVB-S6-500 combined with PAC in subjects with platinum-resistant, recurrent ovarian cancer. “Investigational” means that the study drug is currently being tested and is not yet approved by the United States (U.S.) Food and Drug Administration (FDA). AVB-S6-500 is a drug containing a protein that is designed to interfere with the ability of cancer cells to invade other parts of the body (also called metastasis) by binding to a cell protein called GAS6. This protein, GAS6, is found in everyone, but in cancer patients it works to allow tumors to invade other parts of the body.

This study is currently enrolling.